Technical Data
G8951-31
Granulocyte Macrophage Colony Stimulating Factor Receptor, alpha, Recombinant Human (GM-CSF R , CD116)
50ug
Growth Factors, Cytokines Storage: -20°CShipping: Blue Ice
Granulocyte macrophage colony stimulating fact or receptor alpha (GM­CSF R ) , also known as CD116, is a component of the receptor complex that mediates cellular responses to GM­CSF. GM­CSF promotes the differentiation and mobilization of granulocyte­macrophage, erythroid, megakaryocyte, and eosinophil progenitors. It enhances the activation of myeloid cell effect or functions and plays a role in the development of Th1 biased immune responses, allergic inflammation, and autoimmunity (1 ­ 4). Mature human GM­CSF R is an 80kD type I transmembrane glycoprotein that consists of a 298 amino acid (aa) extracellular domain (ECD) with two fibronect in type III domains and a juxtamembrane WSXWS motif , a 26 aa transmembrane segment , and a 54 aa cytoplasmic domain (5). Within the ECD, human GM­CSF R shares approximately 33% aa sequence identity with mouse and rat GM­CSF R . Alternate splicing of human GM­CSF R generates several additional isoforms that lack the cytoplasmic and/or transmembrane regions. Soluble forms of the receptor retain the ability to bind GM­CSF ( 6, 7) . GM­CSF R is expressed on hematopoieticstem cells, progenitor and differentiated cells in the myeloid lineage, vascular endothelial cells, placenta, and non­hematopoietic solid tumor cells (8). GM­CSF R associates with the common beta chain/CD131 ( c ), a135kD transmembrane protein that is also the signal transducing component of the receptors for I L­3 and IL­5 (9,10). Association with c convert s GM­CSF R from a low affinity to a high affinity receptor for GM­CSF ( 9 ­ 11). The shared usage of c underlies the synergism between GM­CSF, I L­3, and I L­5 in their effects on myeloid cell differentiation and activation (1, 2).

Recombinant protein corresponding to human Leu20-Gly320, with a C-terminal 10-His tag expressed in NSO cells (P15509)

Activity:
Measured by its ability to inhibit GMCSFdependent proliferation of TF1 human erythroleukemic cells. The ED50 for this effect is typically 1.25ug/ml in the presence of 40pg/ml of rhGMCSF.

Applications:
Suitable for use in ELISA. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile buffer. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
36.2kD
Purity: 95% by SDS­PAGE under reducing conditions and visualized by silver stain. Endotoxin: 0.01EU per 1ug of the protein by the LAL method.
Concentration: ~0.5mg/ml (after reconstitution)
Form: Supplied as a lyophilized powder. Reconstitute with 100ul sterile PBS.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. MartinezMoczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. 112:653.
2. Fleetwood, A.J. et al. (2005) Crit. Rev. Immunol. 25:405.
3. Eksioglu, E.A. et al. (2007) Exp. Hematol. 35:1163.
4. Cao, Y. (2007) J. Clin. Invest. 117:2362.
5. Gearing, D.P. et al. (1989) EMBO J. 8:3667.
6. Pelley, J.L. et al. (2007) Exp. Hematol. 35:1483.
7. Raines, M.A. et al. (1991) Proc. Natl. Acad. Sci. 88:8203.
8. Chiba, S. et al. (1990) Cell Regul. 1:327.
9. Kitamura, T. et al. (1991) Proc. Natl. Acad. Sci. 88:5082.
10. Hayashida, K. et al. (1990) Proc. Natl. Acad. Sci. 87:9655.
11. Hoang, T. et al. (1993) J. Biol. Chem. 268:11881.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.